Arizona State University

Arizona Board of Regents, a Body Corporate

Qiang Chen

Charles Joel Arntzen

Hugh S Mason

Zhong Huang

Huafang Lai

Brooke Hjelm

Ming Yang

Shuo Yuan

Junyun He

Jonathan Hurtado

Haiyan Sun

The present invention relates to the fields of genetically modifiedstrains, vaccine adjuvants, and generally molecular biology and immunology. Provided herein are modifiedstrains that produce lipopolysaccharide (LPS) having reduced toxicity or detoxified lipopolysaccharide, and methods of obtaining such strains for plant-based production of biologies. Also provided herein are uses of reduced or detoxified LPS as adjuvants suitable for clinical use.

Reducing the toxicity of agrobacterium endotoxin

Compositions including a virus-like particle (VLP)-based vaccine displaying a portion of ZIKV envelope protein (E) domain III (DIII) and a portion of ZIKV envelope protein (E) and related methods are disclosed herein. Further, compositions including vaccines comprising a portion of ZIKA virus E protein, wherein the portion of ZIKA virus E protein is either a full-length version of ZIKA virus E protein or a functionally equivalent version of the full-length ZIKA virus E protein, are disclosed.

Vaccines against Zika virus based on Zika structure proteins

The present invention describes the plant-based production of a therapeutic anti-virus antibody.

Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ADE) of infection

Plant viral vectors have great potential in rapid production of proteins, but no simple Here a geminivirus-based system for high-yield and rapid production of oligomeric protein complexes, including virus-like particle (VLP) vaccines and monoclonal antibodies (mAbs) is described. In particular, a single vector that contains two non-competing replicons for transient expression inleaves is described. The correct assembly of these subunit proteins into functional oligomeric structures (VLPs or full-size mAb) is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of this technology for producing multiple-subunit protein complexes.

DNA replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants

The plant-based production of a therapeutic antibody against West Nile Virus is disclosed.

Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration

The present invention describes the plant-based production of a therapeutic antibody against West Nile Virus.

Production of a monoclonal antibody therapeutic against west nile virus in plants

Plant viral vectors have great potential in rapid production of proteins, but no simple. Here a geminivirus-based system for high-yield and rapid production of oligomeric protein complexes, including virus-like particle (VLP) vaccines and monoclonal antibodies (mAbs) is described. In particular, a single vector that contains two non-competing replicons for transient expression inleaves is described. The correct assembly of these subunit proteins into functional oligomeric structures (VLPs or full-size mAb) is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of this technology for producing multiple-subunit protein complexes.

Growing community of inventors

Chandler, AZ, United States of America

Qiang Chen